Alphabet’s Isomorphic Labs, spun out of DeepMind, is preparing to start human trials of AI-designed drugs after raising $600 ...

One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for a drug to ...

Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are ...

Alphabet's AI drug development subsidiary Isomorphic Labs is aiming to initiate clinical trials for its AI-developed oncology drugs. In an interview with Fortune, Isomorphic Labs president Colin ...

Isomorphic Labs, Google’s artificial intelligence drug business, raised $600 million in its first external funding round, the company said on Monday. Thrive Capital, a venture capital firm, led ...

Google DeepMind is getting ready to begin human testing of drugs developed using artificial intelligence. All you need to ...

Alphabet has now taken that advancement and created a new company called Isomorphic Labs, focused on AI-driven drug discovery. This commercial venture was founded and is currently led by DeepMind ...

Isomorphic Labs Inc., a healthcare startup that spun out of Alphabet Inc. in 2021, today announced that it has closed a $600 million funding round.OpenAI backer Thrive Capital led the investment.

Isomorphic Labs, an Alphabet-backed AI biotech firm, raised $600M to boost its AI drug design engine, expand clinical programs, and accelerate disease research.

Isomorphic Labs, a subsidiary of Alphabet Inc., said it entered into strategic research collaboration agreements with Novartis AG and Eli Lilly & Co.

The latest to do so is Google parent company Alphabet, which has established Isomorphic Labs, under DeepMind head Demis Hassabis, to take its shot at the promising new field.

Isomorphic Labs isn’t the first or only company to say it plans to streamline drug development with the help of AI. Since 2012, a startup out of the University of Toronto called Atomwise has had ...